How big is the global diabetes-associated ophthalmic treatment market?

The global diabetes-associated ophthalmic treatment market was estimated at USD 27.30 billion in 2023, is expected to surpass around USD 52.22 billion by 2033.

Who are the key players in the global diabetes-associated ophthalmic treatment market?

The major players operating in the diabetes-associated ophthalmic treatment market are Alcon; Johnson & Johnson Services, Inc.; Bausch Health; Allergan; Bayer AG; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer, Inc.; Genentech, Inc.; Carl Zeiss Meditec; Lumenis; Ellex Medical Lasers Ltd.; IRIDEX Corporation; Topcon Corporation; Abbott Medical Optics; Quantel.

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Type (Drugs, Devices), By Application (Dry Eye, Glaucoma, Diabetic Retinopathy, DAMD, Uveitis, Cataract), By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

Q: What is the diabetes-associated ophthalmic treatment market growth?

The global diabetes-associated ophthalmic treatment market is expected to grow at a compound annual growth rate of 6.7% from 2024 to 2033 to reach USD 52.22 billion by 2033.

Report Details

Report Code:6130
Category:Medical Devices
No. of Pages:150+
Format:PDF/PPT/Excel
Published:April 2025
Historical Year:2021-2023
Base Year:2024
Estimated Year:2025-2034

Get a Sample

Proceed To Buy

Global Deep Dive Analysis

USD 4500

Single Region (NA,EU,APAC,LA,MEA)

USD 3900

Databook

USD 1900

Competitive Intelligence

USD 1200

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others

Ask To Expert